Directed evolution of anti-HER2 DARPins by SNAP display reveals stability/function trade-offs in the selection process by Houlihan, Gillian et al.
Original Article
Directed evolution of anti-HER2 DARPins by
SNAP display reveals stability/function trade-offs
in the selection process
Gillian Houlihan1,2, Pietro Gatti-Lafranconi1, David Lowe2,
and Florian Hollfelder1,*
1Department of Biochemistry, University of Cambridge, 80 Tennis Court Road, Cambridge CB2 1GA, UK, and 2MedImmune
Ltd, Milstein Building, Granta Park, Cambridge CB1 6GH, UK
*To whom correspondence should be addressed. E-mail: fh111@cam.ac.uk
Edited by Jacques Fastrez
Received 28 November 2014; Revised 5 May 2015; Accepted 7 May 2015
Abstract
In vitro display technologies have proved to be powerful tools for obtaining high-afﬁnity protein
binders. We recently described SNAP display, an entirely in vitro DNA display system that uses
the SNAP-tag to link protein with its encoding DNA in water-in-oil emulsions. Here, we apply
SNAP display for the afﬁnity maturation of a designed ankyrin repeat proteins (DARPin) that binds
to the extracellular domain of HER2 previously isolated by ribosome display. After four SNAP display
selection cycles, proteins that bound speciﬁcally to HER2 in vitro, with dissociation constants in the
low- to sub-nanomolar range, were isolated. In vitro afﬁnities of the panel of evolved DARPins direct-
ly correlated with the ﬂuorescence intensities of evolved DARPins bound to HER2 on a breast cancer
cell line. A stability trade-off is observed as the most improved DARPins have decreased thermo-
stability, when compared with the parent DARPin used as a starting point for afﬁnity maturation.
Dissection of the framework mutations of the highest afﬁnity variant, DARPin F1, shows that
functionally destabilising and compensatory mutations accumulated throughout the four rounds
of evolution.
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Introduction
Screening and selection technologies have been fundamental for the
isolation of antibodies and other binding proteins (Hoogenboom,
2005; Leemhuis et al., 2005; Bradbury et al., 2011; Colwill and
Graslund, 2011). The availability of high-afﬁnity binding molecules
with exquisite target speciﬁcity has led to their widespread use in diag-
nostics (Schellekens et al., 2000) and therapeutics (Chan and Carter,
2010). Next-generation antibodies including antibody-drug conju-
gates, biosuperiors and multispeciﬁc antibodies hold promise for
greater clinical efﬁcacy (Beck, 2011; Buss et al., 2012; Evans and
Syed, 2014). However, antibody fragments often have limited stabil-
ity, a tendency to aggregate and require an oxidising environment for
structurally critical disulﬁde bonds to form, therefore complicating
recombinant expression (Lowe et al., 2011). Binding scaffolds with su-
perior biophysical properties have been engineered as alternatives for
molecular recognition (Binz et al., 2003; Gebauer and Skerra, 2009).
These alternatives include designed ankyrin repeat proteins
(DARPins), designed leucine-rich repeat proteins with varying curva-
tures (Ramisch et al., 2014), afﬁbodies (Nord et al., 1997; Boersma
and Plückthun, 2011), monobodies (Koide et al., 1998), cystine-knot
miniproteins (Kolmar, 2009) and anticalins (Beste et al., 1999). Such
scaffolds consist of a characteristic framework that presents surface
loops with randomised regions, setting up potential binding interfaces
to interact with different target antigens.
One class of alternative scaffolds, DARPins, are derived from the
ankyrin repeat motif, which modulates a plethora of binding
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interactions in bacteria, archaea and eukarya (Mosavi et al., 2004).
Repeats consist of a β-turn followed by two antiparallel α-helices
and a loop connecting the next helix. A consensus design approach
based on sequence and structural alignments of natural ankyrin repeat
proteins was adopted to design modules consisting of conserved
framework positions and randomised potential target interaction
positions at the binding interface. The designed DARPins were well-
expressed proteins with high thermodynamic stabilities. DARPin
libraries with different numbers of internal repeated modules were
constructed with ﬂanking charged N- and C-terminal caps to shield
the hydrophobic core (Binz et al., 2003). High-afﬁnity binders for a
number of globular proteins have been successfully isolated by both
ribosome and phage display (Binz et al., 2004; Sennhauser et al.,
2007; Steiner et al., 2008).
While all panning selections from display libraries are carried out
in vitro, the display technology may have an inﬂuence on the selection
outcome, because the quality of the display is correlated to the avail-
able genetic diversity that can be explored. For example, translocation
in phage display and ternary complex stability in ribosome display are
requirements for successful display, and can bias a selection campaign
by restricting the level of diversity that can be screened. To assess the
utility of an alternative technology, we now apply SNAP display (Stein
et al., 2007; Kaltenbach and Hollfelder, 2012; Houlihan et al., 2014)
for the isolation of DARPins binding the HER2/neu transmembrane
tyrosine kinase receptor. SNAP display is a cell-free DNA display
system, which uses water-in-oil droplets to compartmentalise single
DNA library members (Fig. 1) (Stein et al., 2007; Schaerli and
Hollfelder, 2009; Houlihan et al., 2013). A covalent linkage is created
in emulsion droplets by chemical reaction of an in vitro-expressed
O6-alkylguanine DNA alkyltransferase (AGT)-DARPin fusion with
BG-labelled DNA templates (Juillerat et al., 2003; Keppler et al.,
2003). SNAP display exists in several formats, which, for example,
take advantage of avidity during selection (Kaltenbach et al., 2011)
or enable quantitative binding selections based on ﬂuorescence detec-
tion of megavalent constructs [BeSD, see (Diamante et al., 2013)]. The
covalent nature of the SNAP display construct yields the DNA of each
binding hit even under panning conditions that would lead to disinte-
gration of non-covalent constructs. The stability of DNA (rather than
RNA) should also facilitate robust library recovery during selection.
Other display technologies including ribosome (Zahnd et al., 2007a,
b; Douthwaite and Jackson, 2012; Dreier and Plückthun, 2012;
Plückthun, 2012), mRNA (Keefe and Szostak, 2001), DNA (Doi
and Yanagawa, 1999) and mHaeIII (Bertschinger et al., 2007) display
have already been previously employed in directed evolution cam-
paigns, while library selections by SNAP display remain to be shown.
Here, we report the ﬁrst successful application of SNAP display for
the in vitro evolution of DARPins targeting the extracellular domain
of HER2. The target protein, HER2, is involved in regulating cell
growth, survival, adhesion and differentiation (Yarden, 2001) and
found to be overexpressed on the tumour cell surface in∼20% of all
Fig. 1 SNAP display selection scheme. (1) Water-in-oil emulsion droplets compartmentalise DNA library members separately, such that one gene (or none) is
Poisson-distributed in droplets. In vitro expression is performed from single linear DNA templates. (2) The SNAP-tag forms a covalent thioether bond between
the protein-coding DNA (bearing a covalently-linked SNAP-substrate, benzylguanine, BG) and the corresponding expressed protein (Keppler et al., 2003). The
stability of the covalent genotype–phenotype linkage enables panning selections (3) to be performed under a wider range of conditions without the risk of
disassembly of genotype and phenotype. Panning conditions are tuned to achieve the required level of stringency for the isolation of binders (4). The DNA
recovered from selections is ampliﬁed by PCR (5). After each round of selection, additional mutations are easily introduced during PCR by low ﬁdelity
polymerases. Reproduced with permission from Houlihan et al. (2014).
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human breast cancers (Slamon et al., 1987), which results in an aggres-
sive phenotype with a poor clinical outcome for patients (Winstanley
et al., 1991). Trastuzumab (Herceptin), a monoclonal antibody that
binds to domain IV of HER2, has an antiproliferative effect on cells
overexpressing HER2 and is currently used as a treatment for breast
cancer (Slamon et al., 2001). Despite the clinical success of
Trastuzumab, a signiﬁcant proportion of patients acquires resistance
within 1 year of treatment (Albanell and Baselga, 2001;
Montemurro et al., 2006). Hence, there is a strong argument to de-
velop new binders and strategies to ﬁnd alternative ways of overcom-
ing resistance (Schrama et al., 2006).
Starting from DARPin G3-HAVD (Zahnd et al., 2006), which
binds with sub-micromolar afﬁnity to the extracellular domain of
HER2, afﬁnity maturation was performed by SNAP display.
Starting with libraries of >109 variants, four rounds of SNAP display
selection cycles yielded binders with dissociation constants for
the extracellular domain of HER2 in the low- to sub-nanomolar
range, and that also bind to the HER2 receptor on cells. The most
improved variant, DARPin F1, accumulated nine mutations through-
out the maturation process and had an almost 700-fold increase in af-
ﬁnity compared with its parent. We observe a stability trade-off as the
most improved DARPins have decreased thermostability, when com-
pared with the parent DARPin used as a starting point for afﬁnity
maturation.
Materials and methods
Error-prone polymerase chain reaction
The pQE30 plasmid containing the gene encoding DARPin
G3-HAVD was used as a template for error-prone polymerase chain
reaction (PCR) using the GeneMorph II random mutagenesis kit
(Agilent Technologies). The PCR was performed under conditions
that maintained a low mutation rate (0–4 mutations per gene; accord-
ing to the manufacturer’s recommendations) using a forward primer
(5′-TTGGGAGGTACCGGCGGTCTG-3′) containing a KpnI site
and reverse primer (5′-GTTAGCAGCCGGATCCTCACTATAAC-3′)
containing a BamHI site. Brieﬂy, a 50 µl reaction contained template
DNA (1 µg), dNTPs (200 µM), forward and reverse primers (2 µM),
Mutazyme II reaction buffer (1×) and Mutazyme II DNA polymerase
(2.5 U). Thermal cycling consisted of an initial heat activation step for
2 min at 95°C followed by 30 cycles of denaturation at 95°C (30 s),
annealing at 54°C (1 min) and extension at 72°C (1 min) followed
by a ﬁnal elongation step at 72°C (10 min). The PCR product was di-
gested with DpnI (NEB) to remove any remaining plasmid and puri-
ﬁed using the QIAquick PCR puriﬁcation kit (QIAgen). A portion
of the library was used for reassembly (see below), while another por-
tion was cloned into pIVEX to determine the mutation rate by sequen-
cing 15 randomly picked colonies.
DARPin library construction
In separate PCR steps (see Supplementary Fig. S1A), the assembly
fragments (5′ untranslated region-AGT and 3′ untranslated region)
were ampliﬁed with primers 5′-UTR fwd (5′-CCGCCGGTACC
TCCCAAGCCTG-3′), 5′-UTR rev (5′-TGGCGAAAGGGGGAT
GTGC-3′), 3′ UTR fwd (5′-AGTGAGGATCCGGCTGCTAAC
AAAGCC-3′) and 3′ UTR rev (5′-TGCTAGCGCTATATGCGTT
GATGC-3′), respectively, from the plasmid pIVEX-AGT-DHFR
using Pfu Ultra II polymerase (Agilent Technologies). Identical
thermo-cycling conditions were used as above apart from the anneal-
ing temperatures (60°C). After DpnI digestion and puriﬁcation of the
amplicons, the library was assembled by overlap extension PCR using
the PCR fragments from the separate ampliﬁcation steps described
above using the primers LMB 2-6 (5′-ATGTGCTGCAAGGCG
ATTAAG-3′) and pIV-BG (5′-BG-GCGTTGATGCAATTTCTA
TGC-3′). The ﬁnal construct was subjected to PEG-MgCl2 precipita-
tion, as described in Stein and Hollfelder (2009) to remove any
remaining primer-dimers. Samples were run on an agarose gel to
conﬁrm DNA fragments with the correct size were ampliﬁed (see
Supplementary Fig. S1B).
Afﬁnity selections using SNAP display
In vitro transcription and translationwere performed as previously de-
scribed (Houlihan et al., 2014). Brieﬂy, 5 ng of DNA were added to
the in vitro transcription and translation (IVTT) mix [PURExpress,
NEB (Kanamori et al., 2014)], then homogenised in ice-cold mineral
oil mix [95% mineral oil (Sigma-Aldrich), 4.5% Span 80 (w/w)
(Fluka), 0.5% Tween 80 (w/w) (Sigma)]. The emulsion was incubated
at 25°C for 4 h, then the aqueous phase extracted in recovery and
binding buffer [phosphate buffered saline (PBS) supplemented with
5 mM EDTA and 10 μM BG]. The displayed protein library was
incubated with biotinylated HER2 (purchased from R&D Systems,
cat. no. 1129-ER-050) and captured on streptavidin-coated beads
(Dynal). Biotinylation of HER2 was performed as described in
Houlihan et al. (2014). After incubation for 1 h, streptavidin beads
were washed (ﬁve times with PBS supplemented with Tween 20,
0.01% v/v) and remaining HER2-bound DARPins were eluted with
KOH (6 mM). Recovered DNA was ampliﬁed using the primers
sel-fwd (5′-TTGGGAGGTACCGGCGGTCTG-3′) and sel-rev (5′-
GTTAGCAGCCGGATCCTCACTATAAC-3′) and reassembled as de-
scribed above. DNAwas puriﬁed usingQIAquick PCR puriﬁcation kit
(QIAgen), precipitated with PEG-MgCl2 and used in the following
round of selection or cloned into pQE30 for sequencing.
qPCR of selection outputs
DNA was quantiﬁed using a Rotor-Gene 6000 machine (Corbett
Research). Three microlitres of a selection output were used in a real-
time mix consisting of 1× Sensimix SYBR no-rox (Bioline) and primers
Fwd-DARPin-50 (5′-AGGCTTGGGAGGTACCG-3′) and DARPin-
rtpcr-rev (5′-GCTAAGTGAAGAGGGGTTAG-3′). Cycling conditions
were as follows: 40 cycles of denaturation at 95°C for 15 s, annealing at
55°C for 15 s and extension at 72°C for 20 s.
Site-directed mutagenesis of DARPin F1 to revert
mutated residues
DARPin F1 was mutated using non-overlapping oligonucleotides that
contained the desired mutation during whole plasmid PCR. The amp-
liﬁed DNAwas digested with DpnI, treated with T4 PNK, ligated into
pQE30 using the restriction enzymes BamHI and HindIII and trans-
formed into M15 cells for protein expression. DARPin F1 mutants
were expressed and puriﬁed as described above.
Protein expression and puriﬁcation
SNAP display-selected DARPins were cloned into the plasmid pQE30
(QIAgen) downstream of a hexa-histidine tag using primers DARPin-1
(5′-ACGTACGATCCGATCTAGGCAAGAAACTACTTGAGGC-3′)
and DARPin-2 (5′-AATTAAGCTTTCACTATAACTTTTGGAGAA
TTTCAGCCAG-3′). Clones were transformed and expressed in the
bacterial strain, M15. For small-scale expression, overnight cultures
were added to 10 ml LB media and grown until an OD600 of 0.6
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was reached. Protein expression was induced with 1 mM IPTG and
cells were grown at 37°C for 4 h. Cells were centrifuged at 6000g
for 10 min at 4°C. Pellets were resuspended in lysis buffer (1× bugbus-
ter, 40 mM imidazole, 1× PBS) and puriﬁed using His trap spin col-
umns (GE healthcare), which yielded >90% pure protein. For
large-scale puriﬁcation, DARPins were expressed on a 1 l scale and
puriﬁed using afﬁnity chromatography (HisTrap ff crude columns -
GE healthcare). DARPins were further puriﬁed with a size-exclusion
chromatography step using a Superdex 75 column (GE healthcare).
For competition experiments, DARPin H10-2-G3 was cloned into
the plasmid pASK-IBA5plus downstream of a Strep-Tactin tag using
BamHI andHindIII cloning sites. Top 10E.coli cells were transformed
with the plasmid and a single colony was grown overnight at 37°C in
LB media. The LB media (10 ml) was inoculated with overnight cul-
tures and grown until an OD600 of 0.6 was reached and induced with
0.2 μg/ml anhydrotetracycline. The cells were harvested by centrifuga-
tion and resuspended in buffer W (100 mM Tris–HCl, pH 8.0, con-
taining 150 mM NaCl and 1 mM EDTA). Strep-tagged DARPin
H10-2-G3 was puriﬁed using Strep-Tactin spin columns (IBA Life
sciences) according to the manufacturer’s instructions.
ELISA (crude and soluble)
For ELISA screening, selected DARPins from SNAP display outputs
were ampliﬁed by PCR using the primers DARPin-1 (5′-ACGTACG
ATCCGATCTAGGCAAGAAACTACTTGAGGC-3′) and DARPin-2
(5′-AATTAAGCTTTCACTATAACTTTTGGAGAATTTCAGCCA-
G-3′), cloned into the plasmid pQE30 (QIAgen) and used to theE. coli
strain M15. Individual colonies were picked and grown in a 96-deep
well plate in 200 μl of LB medium overnight at 37°C. After addition of
1.3 ml media, cells were grown until an OD600 of 0.6 was reached.
Protein expression was inducedwith IPTG (1 mM ﬁnal concentration)
and cells were grown for a further 4 h at 37°C. Cells were harvested by
centrifugation at 6000g for 10 min at 4°C. Cell pellets were lysed with
50 μl 1× Bugbuster (Merck-Millipore) per well and centrifuged to pel-
let any remaining cellular debris. The crude extract was diluted with
450 μl PBS, 100 μl was added to a streptavidin-coated 96-well plate
(Thermo scientiﬁc) previously coated with biotinylated HER2 and in-
cubated for 1 h at room temperature. All wells were washed ﬁve times
with PBS supplemented with Tween 20 (0.01%). An RGS-anti-His
antibody conjugated to horseradish peroxidase (HRP) (QIAgen) was
diluted 1:2000 in blocking buffer (QIAgen) and 50 μl added to each
well. Colorimetric detection was done by the addition of 50 μl of
the substrate, 3,3′,5,5′-tetramethylbenzidine (Sigma) and the reaction
was stopped with 50 μl of 0.5 M H2SO4.
For soluble ELISAs, the procedure outlined above was performed
using 10 μg/ml of puriﬁed DARPin in place of crude extract. For spe-
ciﬁcity ELISAs, the same procedure as soluble ELISAs were performed
but streptavidin wells were coated with different antigens. For com-
petition ELISA with DARPin H10-2-G3 (strep-tag), the evolved
DARPins (His-tagged) were combined with 150 nM DARPin
H10-2-G3 and the level of HER2-bound DARPin (His-tagged) was
measured as above.
Bio-layer interferometry
KD values were determined by bio-layer interferometry using an Octet
Red instrument (ForteBio, Inc.). Biotinylated HER2 (10 μg/ml) in 1×
kinetics buffer (PBS, pH 7.4, 0.01% bovine serum albumin (BSA) and
0.01% Tween 20) was loaded onto streptavidin-coated biosensors
(ForteBio, Inc., 18-5020) and incubated with DARPins in kinetics buf-
fer. A titration of eight different DARPin concentrations was used to
measure kinetics with the highest concentration starting from 50 nM.
Each measurement consisted of ﬁve steps: baseline acquisition, 60 s;
HER2 loading onto SA sensor, 300 s; baseline acquisition, 60 s; asso-
ciation of DARPin, 300 s; dissociation of DARPin, 300 s. Baseline and
dissociation steps were performed in kinetics buffer. All steps were
performed with sample agitation at 1000 rpm. Binding kinetics were
determined using a 1:1 Langmuir-binding model in kinetics data ana-
lysis mode using the Fortebio data processing software.
Tissue culture and ﬂow cytometry
The breast cancer cell line SK-BR-3 (ATCC) was cultured in McCoy’s
5amodiﬁedmedium supplemented with 10% foetal bovine serum and
grown in 5% CO2 at 37°C. The cells were dissociated from the ﬂask,
centrifuged at 1200g for 5 min at 4°C and the pellet resuspended in
sterile PBS. Cells were transferred to 96-well tissue culture plates
(5 × 106 cells per well) and stained with LIVE/DEAD Fixable Aqua
Stain (Invitrogen) (100 μl/well) for 30 min protected from light.
Cells were washed with ﬂow cytometry staining (FCS) buffer and
centrifuged at 1200g for 5 min. DARPins and controls were added to
the cells (1 µg/ml) and incubated for 1 h at room temperature. The
cells were centrifuged at 1200g for 5 min, pellets were resuspended in
100 μl of an anti-histidine tagged antibody (Millipore 05-949) (5 μg/
ml) and incubated for 60 min in the dark. After washing in FCS buffer,
the cells were resuspended with a goat anti-mouse R-phycoerythrin-
conjugated secondary antibody (Jackson Immunoresearch 115-
116-146) and incubated for 60 min in the dark. Trastuzumab- and
Cat002-treated cells were resuspended with a goat anti-human mouse
R-phycoerythrin-conjugated secondary antibody (ebioscience 12-4998)
and incubated for 60 min in the dark. After washing with FCS buffer,
the cells were ﬁxed by addition of 3.7% formaldehyde solution. Cells
were washed with PBS and subjected to ﬂow-cytometric analysis using
a FACSCanto II instrument (BD Biosciences). Fluorescence was detected
at 525 nm after excitation at 405 nm. The data were analysed using
FlowJo software. The Herceptin sample used for comparison in
Supplementary Fig. S3 was a commercial preparation from Roche
Pharma AG.
Thermostability measurements using differential
scanning ﬂuorimetry
Differential scanning ﬂuorimetry was used to measure DARPin un-
folding by monitoring SYPRO Orange ﬂuorescence. Puriﬁed
DARPins were diluted to 5 µM in a Tris buffer (Tris 50 nM and
NaCl 150 nM, pH 7.5). SYPRO Orange dye (Invitrogen) was used
at a ﬁnal concentration of 20×. Melting curves were recorded over
a temperature range of 25–99°C (in triplicate 20 µl reaction volumes)
using a real-time PCR machine (Rotor-Gene 6000, Corbett Research)
with ﬁlters to excite at 460 nm and measure emission at 510 nm as the
temperature continually increased (ramp rate of 1°C/min). Data were
ﬁtted using GraphPad Prism software.
Results and discussion
Afﬁnity maturation of an anti-HER2 DARPin using
SNAP display
The starting point for afﬁnity maturation via SNAP display was
DARPin G3-HAVD, an anti-HER2 binder previously isolated by
ribosome display (KD of 269 nM) from the N2C consensus designed
ankyrin repeat library (Zahnd et al., 2007a,b). We used random
mutagenesis by error-prone PCR and tuned selection stringency by
varying the target protein concentration to select for variants with
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higher afﬁnity. As SNAP display is a fully in vitro system, it provides
access to both of these features. Ligation- and transformation-
independent assembly of the SNAP display construct via overlap
PCR (Supplementary Fig. S1) allows the construction of large libraries
without introducing mutations in regulatory regions. The recently
published improved protocol (Houlihan et al., 2014) guided the imple-
mentation of stringent washing conditions, antigen concentration
modulation and DNA recovery quantiﬁcation required for successful
selection. Brieﬂy, 109 DNA molecules from the reassembled library
were used as DNA input for selection against soluble, recombinantly
expressed HER2 (extracellular domain only) immobilised on
streptavidin-coated beads. Four rounds of SNAP display selections
were performed, with lowering antigen concentrations from 100 to
1 nM to increase the stringency during selections (Schier et al.,
1996; Scott and Smith, 1990) (Table I). The polymerase used for amp-
liﬁcation was alternated between Taq andMutazyme at each round to
introduce either on average very few [0.1 mutations per kb per cycle
for Taq (Tindall and Kunkel, 1988)] or two amino acid mutations
per protein (for Mutazyme). To monitor enrichment, DNA recovery
(as measured by qPCR) was compared between selections performed
in the presence and absence of ligand (Table I).
Improved anti-HER2 DARPins selected by SNAP
display reveal mutational hotspots
To determine the number of bona ﬁde binders, 96 individual colonies
from the initial library, round 2 and 4 outputs were separately cloned,
expressed as soluble DARPins in M15 cells and ELISA screened in
crude extract for binding to HER2. The initial library contained
2% clones with similar binding signal as the parent clone, while
this number rose to 72% in round 4 (a 30-fold increase; Fig. 2). In
round 4, 30% of the clones gave ELISA signals greater than the ori-
ginal DARPin, consistent with ribosome (Hanes et al., 1998) and
phage display (Brockmann et al., 2011) outputs. The increase in
hits suggests that SNAP display is capable of isolating improved
HER2-binding DARPins from large epPCR-generated libraries.
Sequence analysis of the DARPins that gave the highest signals in
the crude extract ELISA (Fig. 2) indicated that selected clones had be-
tween two and nine amino acid changes scattered across the entire se-
quence compared with the parent DARPin (Supplementary Fig. S2).
The majority of mutations are found in framework positions while
only four (<10%) are found in originally randomised positions.
Mutations cluster in the ﬁrst helix of the ﬁrst repeat and C-cap indi-
cating these as potential binding hotspots (as conﬁrmed by the muta-
tional analysis of the top 60 isolated DARPins, Fig. 3A). Two
positions in the ﬁrst repeat, His52 and Ala55, are mutated in over
half of the selected DARPins, indicating that optimisation of these po-
sitions is important for improving afﬁnity. The mutation H52Y was
also selected during evolution of the same parent clone using ribo-
some display and was found to directly interact with HER2 (Jost
et al., 2013). Isolation of different DARPins with distinct mutations
indicates that there are multiple solutions/trajectories to improve the
afﬁnity of DARPin G3-HAVD for HER2. However, Fig. 3 shows that
the majority of the highly mutated positions (and all those accumulat-
ing more than 10% variability) fall outside the originally randomised
positions in the designed N2C library, and therefore epPCR was re-
quired throughout the selection process in order to acquire frame-
work mutations.
The high afﬁnity of isolated DARPins is driven
by improved kon values
The 10 binders with strongest signals in the crude extract ELISAwere
afﬁnity puriﬁed. To determine the afﬁnities of the selected clones, puri-
ﬁed proteins were used for the determination of KD using bio-layer
interferometry (Abdiche et al., 2008). All selected variants had im-
proved binding afﬁnities for HER2 compared with DARPin
G3-HAVD (Table II). Four of the binders had afﬁnities in the low-
to sub-nanomolar range, and the remaining variants had KD values
<100 nM. The association rate was the parameter most improved
(100- to 1000-fold) across the panel of DARPins compared with the
published kon of DARPin G3-HAVD (2.75 × 10
3 M−1 s−1). This ob-
servation stands in contrast to previous selections, in which afﬁnity
maturation affected the dissociation rate koff (Yang et al., 1995;
Chen et al., 1999; Jermutus et al., 2001). While typical association
rates for protein–protein interactions are on the order of 105–106
M−1 s−1, the parent DARPin G3-HAVD has an unusually slow kon
(2.8 × 103, i.e. two orders of magnitude slower; Table II). Themost im-
proved variant, DARPin F1, has an afﬁnity three orders of magnitude
greater than the parent clone mainly due to a 1000-fold faster kon that
accounts for most of the observed afﬁnity gain.
Isolated DARPins bind selectively to HER2 in vitro
and on cells
As in vitro selections are typically performed against an immobilised
recombinant target in isolation, there is a risk that non-speciﬁc inter-
actions are preferred, and that binders fail to interact when exposed to
a target on a complex cellular surface. To exclude that non-speciﬁc
binding during the fully in vitro procedure could affect the speciﬁcity
of isolated DARPins, and thus compromise the use of SNAP display
for the development of new therapeutics, speciﬁcity was tested both
in vitro and on mammalian cells overexpressing HER2. Isolated
DARPins were ﬁrst tested in soluble ELISA against streptavidin (the
binding functionality used to capture HER2 on beads during the pan-
ning procedure) as well as lysozyme (a highly charged globular protein
known to provide an easy docking surface for binding). As shown in
Table I. Selection conditions over four rounds of selection using SNAP display
Round Antigen
concentration (nM)
Polymerase Recovery of DNAa DNA recovery—ratio
positive: negativeb
Proportion of bindersc
amongst recovered clones (%)
1 100 Mutazyme 1.2 × 106 46 n.d
2 10 Taq 4.4 × 105 37 5
3 1 Mutazyme 6.7 × 105 74 n.d
4 1 Taq 2.5 × 106 167 30
aNumber of molecules measured by qPCR.
bRatio refers to the recovery in selections in the presence of HER2 (positive) versus selections in the absence of HER2 (negative).
cClassiﬁed based on ELISA signal being greater than that of the parent G3 HAVD.
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Fig. 4A, no binding to either of these targets was detected. However,
when selected DARPins were incubated in the presence of an excess of
the published anti-HER2 DARPin H10-2-G3 (Jost et al., 2013), bind-
ing to HER2 was inhibited. This observation suggests that all SNAP
display evolved DARPins compete, at least in vitro, for the same epi-
tope on HER2, and that the binding regions overlap with that of
DARPin H10-2-G3. To assess whether the high in vitro afﬁnity
could be exploited for therapeutic use, the binding performance
was evaluated in vivo by a cell-based assay with SK-BR-3, an
HER2-positive breast cancer cell line reported to express 106 HER2
molecules per cell. All evolved DARPins showed speciﬁc binding to
HER2 on cells, while no binding was observed for DARPin HDKV,
a DARPin known not to bind to HER2 (Supplementary Fig. S3).
The ﬂuorescence intensities correlate with the afﬁnities of the evolved
panel of binders measured in vitro with soluble HER2 (Fig. 4B). Two
evolved DARPins (F3 and A1) with in vitro afﬁnities lower than
Trastuzumab (Table II) showed higher ﬂuorescence intensities.
While Trastuzumab binds to an epitope on domain IV of HER2 lo-
cated close to the membrane (Cho et al., 2003), the panel of SNAP dis-
play evolved DARPins bind to an epitope located further from the
membrane (Jost et al., 2013). However, the use of different techniques
to attach ﬂuorescent labels means that the number of ﬂuorophores per
protein molecule is not normalised and the intensity readout may not
report on afﬁnity. The accessibility of the different epitopes may ex-
plain the observed difference in binding on cells. Although SNAP dis-
play selections were performed entirely in vitro using recombinant
HER2, the isolated variants are able to recognise and bind their target
when expressed in a complex cellular milieu.
Evidence for a stability/function trade-off during
afﬁnity maturation
In order to analyse how the mutational load imposed on the DARPin
structure is productively used for creating binding interactions, the
Fig. 2 Primary screen of DARPins selected against HER2 using SNAP display. Four rounds of afﬁnity selections were performed and 90 DARPins from the initial
library, second and fourth round were tested for binding in a crude extract ELISA. Binding of DARPins to HER2 was detected using an HRP-conjugated antibody.
The orange line indicates the ELISA signal of DARPinG3-HAVD in each screen. Over 90%of the clones screened gave a signal >5-fold over backgroundwhile∼30%of
the selected DARPins showed greater binding signals compared with the parent DARPin G3-HAVD.
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thermostabilities of the parent and evolved DARPins were measured
using differential scanning ﬂuorimetry (Niesen et al., 2007;
Gatti-Lafranconi et al., 2013). Directed evolution studies on enzymes
have revealed a trade-off between stability and function along evolu-
tionary trajectories (Tokuriki et al., 2008; Thomas et al., 2010). The
thermal stabilities of DARPin variants tend to be decreased compared
with the parent (Fig. 5A). Among the selected mutants that show im-
proved binding, ﬁve are destabilised by greater than 10 degrees
(DARPin F1, C3, F3, G11 and B3), while three other DARPins (A1,
D4 and C4) maintain high levels of stability. The clone with greatest
afﬁnity, DARPin F1, also lost the largest amount of thermal stability
(30°C). A correlation between afﬁnity and stability for DARPins
selected by SNAP display (Fig. 5B) is dominated by the destabilisation
of three of the four most improved mutants, but overall suggests a
trade-off between these parameters. An order of magnitude in binding
strength leads to an ∼8°C loss in stability (albeit with a moderate cor-
relation coefﬁcient r = 0.43). A similar trend is observed when the
number of mutations is plotted against Tm (slope:−0.1188 ± 0.07773
kcal/°C). There is extensive scatter in these plots, presumably reﬂecting
the idiosyncratic effects of individual mutations, but our results are in
line with other examples of stability loss upon gain of improved bind-
ing and extend previous analyses of stability/function trade-offs in
protein binders (Hackel et al., 2008; Karanicolas et al., 2011).
Whilst stabilising mutations have been found in antibodies evolved
Fig. 3 (A) The frequency of mutations measured in the sequenced DARPin mutants is plotted onto the structure of DARPin H10-2-G3 (shown as putty cartoon):
frequently mutated positions are colour-coded and rendered with backbone thickness proportional to mutation rate. Fully conserved positions are shown in
dark blue. The position that accumulated ∼42% of sequence diversity, H52, is shown in red. The positions most frequently mutated are in proximity of the
binding interface. Overall, positions mutated in greater than 10% of the sequenced population are all located in framework positions in the designed N2C
DARPin library. Mutations do, however, map also on framework positions away from the binding interface. The interacting domain of HER2 is represented as a
semi-transparent sand-coloured surface. (B) The published X-ray structure of DARPin H10-2-G3 (green) in complex with HER2 (blue) (Jost et al., 2013) was used
to visualise the likely locations of themutations obtained in DARPin F1. DARPin H10-2-G3was afﬁnitymatured from the same parent clone (DARPin G3 HAVD) as the
DARPins evolved by SNAP display. Mutations that contribute to binding are coloured brownwhile neutral mutations are coloured yellow (see Table III). Figureswere
prepared with Pymol based on PDB 4HRN (Jost et al., 2013).
Table II. Afﬁnities and binding kinetics of the selected HER2-binding DARPinsa
DARPin Mutations kon(M
−1 s−1) koff (s
−1) KD (nM) n-fold KD
improvement
F1 Q26E, I32V, T49A, H52Y, L53H, A55T, V96A, K101R, G124V 9.5 × 105 3.7 × 10−4 0.39 690
F3 N36I, Y46C, H52Y, A55T, D122G 6.3 × 105 1.2 × 10−3 1.9 ± 0.03 140
A1 A22V, D27G, A55T, V76A, K111R, D122G 2.8 × 106 1.1 × 10−2 3.8 ± 0.09 70
C3 H52Y, A55T, A56T, E61G, K114N 1.4 × 106 6.6 × 10−3 4.0 ± 0.05 58
D4 G25R, A55T, G124V 4.2 × 105 6.7 × 10−3 15 ± 0.12 17
C4 E20G, N36D, H52Q, A88T, V106A, T115A, E126G 8.3 × 105 5.3 × 10−2 64 ± 2.0 4
B3 G37D, H52Q, V76M, A104V, D122G, 1.2 × 105 8.7 × 10−3 72 ± 0.28 4
G11 L66M, H102Y, D1104, D127V 7.1 × 105 6.1 × 10−2 86 ± 0.26 3
C2 N36Y, N41D, E61G, L93H, V96A, K101R, G124V 2.8 × 105 2.7 × 10−2 98 ± 0.23 3
Parent G3-HAVDb 2.8 × 103 7.4 × 10−4 269 –
Trastuzumabc 7 × 105 4 × 10−4 0.5 –
aThe data were evaluated with a global kinetic ﬁt. Measurements were performed in PBS buffer supplemented with 0.01% BSA and 0.01% Tween 20 (pH 7.4).
bThese are published descriptors of binding as measured by BIAcore for parent G3-HAVD (Zahnd et al., 2007a,b) and cTrastuzumab (Bostrom et al., 2011).
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during an immune response to compensate for destabilising binding
mutations (Wang et al., 2013), in vitro evolved DARPins show a dif-
ferent behaviour. This may be due to the high stability of DARPins
compared with antibodies and the secondary selection for stability
during in vitro evolution compared with natural evolution.
Analysis of the effects of individual mutations
accumulated in DARPin F1 on binding
afﬁnity and thermal stability
DARPin F1 was chosen for further study because it showed the great-
est afﬁnity improvement and is the least thermostable of the evolved
clones. DARPin F1 shares three mutations (H52Y, A55T, V96A)
with DARPin H10-2-G3 that has a KD in the picomolar range for
HER2 (Zahnd et al., 2007a,b). DARPin F1 also acquired six other
mutations (Q26E, I32V, L53H, T49A, K101R and G124V) through-
out the four rounds of selection (Fig. 3B). As DARPin F1 competes
with DARPin H10-2-G3 for binding to HER2 (Fig. 4A), we assume
that they bind to the same epitope and thus used the crystal structure
of the bound complex to guide our analysis (Jost et al., 2013). To test
the role of each mutation accumulated by DARPin F1 for afﬁnity to-
wards HER2, each mutation was individually reverted to the original
amino acid present in DARPin G3-HAVD and their contribution to
binding in DARPin F1 assessed (Table III). Three mutations were func-
tionally neutral (G124V, T49A and Q26E) while six others (L53H,
I32V, K101R, H52Y, A55T and V96A) contributed almost entirely
to binding only (as indicated by the decrease in afﬁnity when reverted
to their original residues in the parent DARPin, see Supplementary
Table S1). Stability loss upon gain of function is observed for
DARPin F1: its melting temperature is almost 30°C lower than that
of the parent DARPin (Tm = 56.7°C versus Tm = 85.9°C, Fig. 5). The
effects of these nine individual mutations in DARPin F1 are not simply
additive: they add up to an increase in Tm of ∼11°C when individually
reverted, falling short of the observed 30°C of destabilisation when
combined suggesting negative epistasis between destabilising muta-
tions (Olson et al., 2014).
Investigation of the thermal stability of individual revertants re-
vealed that mutations which had the greatest inﬂuence on binding af-
ﬁnity (H52Y, I32V and V96A) also inﬂuenced thermal stability to the
largest extent (when reverted, mutants hadmelting temperatures 4–6°C
greater than DARPin F1, Table III)). Other functional mutations that
contribute to binding to a lesser extent (L53H and K101R) decreased
Fig. 4 (A) ELISA analysis of selected DARPins. The top 10 DARPins (10 μg/ml of
puriﬁed DARPin) were analysed for binding to immobilised HER2. All selected
DARPins from SNAP display outputs gave a greater binding signal than
DARPin G3-HAVD. All evolved DARPins were also analysed for their
speciﬁcity in binding. No binding was observed to Streptavidin (which was
used to capture biotinylated HER2 during selections) or lysozyme indicating
the selected DARPins do not non-speciﬁcally bind to other proteins.
Competition for binding of selected DARPins to HER2 with DARPin H10-2-G3
(10-fold excess DARPin H10-2-G3 over selected DARPins) showed that each
selected DARPin competed for the same epitope as DARPin H10-2-G3.
(B) Correlation between the observed ﬂuorescence values of cell populations
and the reciprocal of their binding afﬁnity shows a correlation between the two
properties. Most notably, Trastuzumab appears to have a signiﬁcantly lower
afﬁnity on cells, probably as a result of the different binding mode and
epitope the antibody binds to on HER2.
Fig. 5 Thermal stability analysis of the selected DARPins. (A) Melting temperatures of the selected DARPins were measured by differential scanning ﬂuorimetry
(plotted based on increase in afﬁnity going from right to left). Measurements were performed in Tris buffer and repeated twice for all mutants. (B) Correlation
between melting temperature and afﬁnity of selected DARPins. An order of magnitude in binding strength leads to a ∼8°C loss in stability (correlation
coefﬁcient r = 0.43; ﬁt not shown).
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thermal stability suggesting their role in DARPin F1 involves both
improving afﬁnity and stabilising the protein (and thus counteracting
the functionally destabilising mutations). Functionally silent muta-
tionsQ26E andG124V both have stabilising effects, while, surprising-
ly, T49A destabilises the protein by 4°C, showing the lack of a
stringent selection for stability (Supplementary Fig. S4). To investigate
the contribution functional mutations have on DARPin F1 thermo-
stability, the mutations that individually do not signiﬁcantly affect
KD (Q26E, T49A andG124V), but have contrasting effects on thermal
stability, have been reverted to give the mutant F1* containing only
mutations that contribute to binding. This mutant showed a moderate
(∼3-fold) decrease in afﬁnity towards HER2, while the melting tem-
perature dropped a further 5°C (Table III). This observation is consist-
ent with the trade-off hypothesis between thermal stability and
binding afﬁnity as it indicates that functionally relevant mutations
had an overall destabilising effect. The functionally neutral but desta-
bilising mutation T49A highlights the weak selection pressure for sta-
bility and the highly stable nature of DARPins that allows them to
tolerate such destabilising mutations, yet sustain function. Thus,
while compensatory stabilising mutations were observed, stability
was not restored to parent DARPin levels, which we hypothesise is
due to the selection pressure for stability being secondary to afﬁnity,
provided a library member is above the minimum thermodynamic sta-
bility threshold.
Conclusions
SNAP display is a powerful tool for afﬁnity maturation
The data presented here constitute the ﬁrst example of the use of
SNAP display for molecular evolution of a binding protein.
Starting from a known binder with high nanomolar afﬁnity for
HER2, we generated diversity by epPCR, selected for binding with
decreasing concentrations of antigen over multiple rounds of in
vitro selections by SNAP display and successfully isolated
sub-nanomolar-binding anti-HER2 DARPins. Screening the outputs
from the SNAP display selection rounds evolved a number of differ-
ent binders that bound HER2 with greater afﬁnity than the parent
clone. The evolved DARPin with highest afﬁnity has a KD almost
700-fold greater than its progenitor. The improved panel of
DARPins validate SNAP display as a platform for directed evolution
of protein binders. Compared to the published ribosome display af-
ﬁnity maturation against HER2 (six rounds including off-rate selec-
tions, (Zahnd et al., 2007a,b)), SNAP display required only four
rounds of 1 h soluble selections to isolate proteins with high afﬁnity.
We speculate that the excess of proteins (∼105 molecules) uncoupled
to the genotype that is produced in each DNA template containing
droplet (Houlihan et al., 2014) leads to highly competitive binding
conditions during panning and may be an unexpected advantage of
afﬁnity selections using SNAP display, given its smaller library size
(up to 1014 in ribosome or mRNA display versus up to 109 in display
methods that rely on droplet compartmentalisation). Other display
technologies that rely on in vitro compartmentalisation have been
utilised for directed evolution of binding proteins, e.g. zinc ﬁnger
binding proteins (Sepp and Choo, 2005), Fab fragments (Sumida
et al., 2012) and src homology 3 (SH3) domains (Bertschinger
et al., 2007) with afﬁnities in the low nanomolar range. The intrinsic
stability of DNA (compared with RNA) and the covalent link
between genotype and phenotype in SNAP display should facilitate
approaches that rely on further modiﬁcation of the displayed protein
(Heinis et al., 2009; Josephson et al., 2014; Passioura et al., 2014)
and in applications beyond, where display constructs are part of
more complex assemblies (Gu et al., 2014). SNAP display is capable
of selecting binders in the sub-nanomolar range and represents a
powerful droplet-based method for directed evolution of protein
binders.
Framework mutations arise during afﬁnity maturation
and contribute to binding
Although repeat proteins have clearly distinguished binding interfaces
that display sets of loops making them exceptionally amenable to ra-
tional redesign, the majority of mutations (47 of 52) in the panel of
afﬁnity matured DARPins are not located in these contact loops, but
instead in framework positions. This is due to the library synthesis by
epPCR that permitted mutations throughout the entire DARPin.
Mutations accumulated by the highest afﬁnity variant, DARPin F1,
are in framework positions located away from the binding interface.
While antibodies typically accumulate somatic mutations in the
CDR loops that are responsible for improved afﬁnities, mutations in
the framework region imply that subtle structural changes may also
lead to afﬁnity increases (Klein et al., 2013). Intra- and inter-repeat in-
teractions found in DARPins, including an extensive hydrogen bond-
ing network are thought to contribute to the extreme stability of these
molecules (Kohl et al., 2003). The side chain of framework residue
His52 forms intra-repeat hydrogen bond with Thr49 and also with
the carbonyl oxygen of residue 81 (a randomised position in the
β-turn of the third repeat). The crystal structure of DARPin
H10-2-G3 (which also contains the H52Y mutation found in some
SNAP display evolved DARPins) shows that H52Y disrupts this
Table III. Position, contribution to stability and afﬁnity of individual DARPin F1 mutationsa
DARPin F1 residue
reversion
Residue positionb KD increase (n-fold) ΔTm (°C) Effect on
binding/stabilityc
Q26E Framework 1.8 6.9 ≈ / +
I32V Framework 243 −2.0 + / −
T49A Framework 0.8 −4.5 ≈ / −
H52Y Framework 160 −6.1 + / −
L53H Framework 7.5 6.8 + / +
A55T Framework 52.5 6.2 + / +
V96A Framework 57.5 −1.5 + / −
K101R Framework 15.5 3.9 + / +
G124V Framework – 0.9 ≈ / +
aSee Supplementary Table S1 for raw values.
bPositions as deﬁned in Zahnd et al. (2007a,b).
c+ indicates an increase in binding and/or afﬁnity. ≈ indicates a mutation is neutral with respect to binding while – signiﬁes a mutation is destabilising.
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hydrogen bonding pattern leading to a 13° rotation of the C-cap and
an adjacent randomised repeat compared with an unmutated DARPin
(Zahnd et al., 2007a,b). As DARPins are designed to be extremely
stable and thus somewhat rigid, structural rearrangements may be re-
quired to increase afﬁnity, which may explain the accumulation of mu-
tations in framework positions, thus corroborating our randomisation
approach combined with SNAP display selections.
The stability of the DARPin structure accommodates
a high mutational load
Thermal denaturation analysis showed that the evolved panel of SNAP
display-selected DARPins are less thermostable than the parent
DARPin G3-HAVD, consistent with other studies of protein binders
that suggested trade-off between stability and function throughout
evolutionary trajectories (Foit et al., 2009; Hackel et al., 2008;
Karanicolas et al., 2011). DARPin G3-HAVD binds HER2 with low
afﬁnity, whilst retaining thermostability levels in the range reported
for members of the naïve library (Zahnd et al., 2006), DARPins
evolved by SNAP display had an afﬁnity gain of three orders of
magnitude in some cases, yet simultaneously lost up to 30°C of ther-
mostability. We ﬁnd that DARPin F1 acquired both functional desta-
bilising mutations (H52Y, I32V and V96A) and compensatory
stabilising mutations (Q26E and G124V) throughout the afﬁnity mat-
uration process in vitro. However, compensatory mutations failed to
restore stability to parent levels. The selection pressure exerted in vitro
throughout SNAP display selections is therefore directed towards
afﬁnity optimisation, while protein stability is secondary. The high
thermal stability of DARPins appears to be key for the success of selec-
tions, because a large mutational load can be accommodated. In this
way, the library can be harvested primarily for the criterion of binding,
before a co-selection for stability constricts the effective library size.
High thermodynamic stability has been shown elsewhere to increase
the mutational robustness and evolvability of proteins (Bloom et al.,
2005; Bloom et al., 2006; Tokuriki and Tawﬁk, 2009; Tracewell
and Arnold, 2009) and DARPins beneﬁt from the ability to readily
accommodate a large number of mutations, emphasising the utility
of the DARPin consensus design for protein evolution. Our selection
strategy stands in contrast to evolution of repeat proteins in Nature.
The modular nature of repeat proteins has led to their evolution
through repeat expansion and homologous recombination without
signiﬁcant impact on structural stability. Consensus design of
DARPins has successfully produced exceptionally stable proteins
due to extensive intra- and inter-repeat interactions (Binz et al.,
2003). Therefore, mutations in the framework are likely to disrupt
such interactions and decrease overall stability. Nonetheless, even
after stability loss upon improved function, evolved DARPins main-
tain high levels of thermostability with the majority exhibiting melting
temperatures > 60°C and are therefore sufﬁciently stable for applica-
tions in diagnostics and therapeutics.
These results illustrate SNAP display as a powerful method for af-
ﬁnity maturation of DARPins, which should enable the rapid develop-
ment of high-afﬁnity proteins targeted to relevant therapeutic targets
and establish it as a part of the protein engineering toolkit.
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